-       Report 
- August 2025
-  191 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- June 2025
-  135 Pages 
- Global 
   From       €2280EUR$2,549USD£2,006GBP 
      €2682EUR$2,999USD£2,360GBP 
            -       Report 
- October 2025
-  198 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  279 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
           -       Report 
- February 2025
-  190 Pages 
- Global 
   From       €4292EUR$4,799USD£3,776GBP 
          -       Report 
- May 2025
-  483 Pages 
- Global 
   From       €5118EUR$5,923USD£4,350GBP 
          -       Report 
- March 2025
- Global 
   From       €4383EUR$4,900USD£3,855GBP 
          -       Report 
- February 2025
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- February 2025
-  150 Pages 
- Global 
   From       €2280EUR$2,549USD£2,006GBP 
      €2682EUR$2,999USD£2,360GBP 
          -       Report 
- June 2025
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- May 2025
-  185 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
          -       Report 
- April 2025
-  185 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
          -       Report 
- March 2025
-  184 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- August 2025
-  197 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- October 2025
-  274 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  138 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- October 2025
-  294 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
       
      RNAi therapy is a type of biotechnology that uses small pieces of RNA to target and silence specific genes. This technology has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNAi therapy works by introducing small interfering RNAs (siRNAs) into cells, which then bind to and degrade messenger RNAs (mRNAs) that encode for specific proteins. This process can be used to reduce the expression of disease-causing genes, or to activate    beneficial genes.
RNAi therapy has the potential to revolutionize the treatment of many diseases, as it is a more precise and targeted approach than traditional drug therapies. It is also less toxic and has fewer side effects. However, the development of RNAi therapies is still in its early stages, and there are many challenges that need to be addressed before they can be widely used in clinical settings.
Some companies in the RNAi therapy market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Moderna Therapeutics. Show Less   Read more